. . . . . . . "[This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-? 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:33+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .